<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764643</url>
  </required_header>
  <id_info>
    <org_study_id>KY20202056-F-1</org_study_id>
    <nct_id>NCT04764643</nct_id>
  </id_info>
  <brief_title>The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy</brief_title>
  <official_title>The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy: a Prospective, Non-inferiority, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lugol chromoendoscopy is essential in detecting and characterizing squamous cell carcinoma of&#xD;
      esophagus. Esophageal irritating symptom has been reported as an common adverse event, which&#xD;
      could be alleviated by sodium thiosulfate solutions. However, sodium thiosulfate was not&#xD;
      widely available. N-acetylcysteine has been previously used as a mucolytic reagent, we&#xD;
      propose that it may also be used to alleviate irritating symptoms caused by Lugo's&#xD;
      chromoendoscopy. A prospective, non-inferior, randomized double-blind clinical trial was&#xD;
      designed to study the efficacy of N-acetylcysteine solutions in relieving esophageal&#xD;
      discomfort .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Visual analogue scale change</measure>
    <time_frame>30 minute after endoscopy</time_frame>
    <description>Visual analogue scale change for esophageal irritation after Lugol chromoendoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with symptom</measure>
    <time_frame>5 minute or 30 minute or 24 hour after endoscopy</time_frame>
    <description>The percentage of patients with symptom after Lugol chromoendoscopy for certain time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralization rate</measure>
    <time_frame>During endoscopy</time_frame>
    <description>Neutralizing effect for residual iodine in esophagus and stomach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>5 minute or 30 minute after endoscopy</time_frame>
    <description>the percentage of heart rate change 5 min or 30 min compared to that Before endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe discomfort rate</measure>
    <time_frame>5 minute or 30 minute after endoscopy</time_frame>
    <description>the percentage of patient with Visual analogue scale over 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exam time</measure>
    <time_frame>during endoscopy</time_frame>
    <description>the time of endoscopy from the beginning of spraying diluted Lugol's solution to end of endoscopy minus time required for biopsy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>sodium thiosulfate solution arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20ml of 5% sodium thiosulfate solution were prepared with 1g sodium thiosulfate crystal dissolved in normal saline in a 20 ml syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine solution arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20ml of 3% N-acetylcysteine solution were prepared with one piece of N-acetylcysteine effervescent tablet （ net weight 0.6g ）dissolved in normal saline in a 20 ml syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine solution</intervention_name>
    <description>use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy</description>
    <arm_group_label>N-acetylcysteine solution arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium thiosulfate solution</intervention_name>
    <description>use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy</description>
    <arm_group_label>sodium thiosulfate solution arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients at risk of esophageal squamous cell cancer including those over 50 years old,&#xD;
             or over 45 years old with family history of esophageal squamous cell cancer;&#xD;
&#xD;
          -  Patients with suspected esophageal lesions by screening endoscopy;&#xD;
&#xD;
          -  Patients requiring surveillance after endoscopic resection or radiotherapy for&#xD;
             esophageal squamous cell cancer one year later。&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients allergic to iodine or with hyperthyroidism;&#xD;
&#xD;
          -  Patients with advanced esophageal cancer, esophageal varices, esophageal ulcer or&#xD;
             other conditions inadvisable for Lugol chromoendoscopy;&#xD;
&#xD;
          -  Patients with severe gastroesophageal reflux disease or reflux symptoms which may&#xD;
             interfered with the outcome measures of current study;&#xD;
&#xD;
          -  Patients with postoperative esophageal stenosis affecting endoscopic observation;&#xD;
&#xD;
          -  Patients with serious comorbidities that cannot tolerate un-sedated gastroscopy;&#xD;
&#xD;
          -  Patients who could not cooperate with the observation including patients with mental&#xD;
             disorders, severe neurosis or dysgnosia;&#xD;
&#xD;
          -  Patients undergoing sedation or general anesthesia during endoscopy.&#xD;
&#xD;
          -  Patients who do not agree to sign informed consent forms or follow the trial&#xD;
             requirement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaohua Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital of Digestive DIsease</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaohua Zhu</last_name>
    <phone>8613991269434</phone>
    <email>sheng2002@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaohua Zhu</last_name>
      <phone>8613991269434</phone>
      <email>sheng2002@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kondo H, Fukuda H, Ono H, Gotoda T, Saito D, Takahiro K, Shirao K, Yamaguchi H, Yoshida S. Sodium thiosulfate solution spray for relief of irritation caused by Lugol's stain in chromoendoscopy. Gastrointest Endosc. 2001 Feb;53(2):199-202.</citation>
    <PMID>11174292</PMID>
  </reference>
  <reference>
    <citation>Gotoda T, Kanzaki H, Okamoto Y, Obayashi Y, Baba Y, Hamada K, Sakae H, Abe M, Iwamuro M, Kawano S, Kawahara Y, Okada H. Tolerability and efficacy of the concentration of iodine solution during esophageal chromoendoscopy: a double-blind randomized controlled trial. Gastrointest Endosc. 2020 Apr;91(4):763-770. doi: 10.1016/j.gie.2019.10.022. Epub 2019 Oct 25.</citation>
    <PMID>31669091</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Zhiguo Liu</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>lugol chromoendoscopy</keyword>
  <keyword>adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Sodium thiosulfate</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

